INTRODUCTION: @entity439 surgery (EVAR) was introduced a decade ago. Early results are promising, however, there remain concerns regarding the longer-term durability of this technique. Consequently, the national multi-centre EVAR trial has been commenced to define the role of endovascular surgery in the management of @entity1028 . DISCUSSION: Successful EVAR requires accurate pre-operative assessment of @entity439 morphology. Current stent-grafts allow 60% of all infra-renal AAA to be treated. Reduced physiological stress and low peri-operative morbidity and mortality rates have been demonstrated with this technique when compared to open repair. Endoleak is an Achilles heel of EVAR, although in itself does not accurately predict outcome. First and second generation devices are estimated to have a 1% per year risk of @entity397 . CONCLUSIONS: Increased understanding of the issues surrounding @entity439 morphology and successful stent-grafting have allowed a major reduction of early type I endoleak. Late endoleak and graft migration remain problematic. @entity1070 are risk factors for subsequent @entity397 although the significance of @entity1070 remains uncertain. More robust indicators of outcome success/failure are required so that follow-up may be rationalised.

Endovascular repair of XXXX : current status.

@entity397 :: ('MESH:D012421', 'Disease') :: ['rupture'] @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysm', 'Endovascular aneurysm'] @entity1028 :: ('MESH:D017544', 'Disease') :: ['abdominal aortic aneurysm'] @entity1070 :: ('MESH:D057867', 'Disease') :: ['type II endoleak', 'Type I and III endoleaks']
@entity1028 :: (MESH:D017544,Disease) :: ['abdominal aortic aneurysm']
